Phio Pharmaceuticals Corp
$ 1.08
5.88%
24 Feb - close price
- Market Cap 15,787,100 USD
- Current Price $ 1.08
- High / Low $ 1.12 / 1.01
- Stock P/E N/A
- Book Value 2.10
- EPS -2.09
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -1.02 %
- 52 Week High 3.48
- 52 Week Low 0.81
About
Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts.
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-01 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-22 |
| Reported EPS | -0.44 | -0.45 | -0.9379 | -0.85 | -1.54 | -3.62 | -0.85 | -0.85 | -1.14 | -1.4747 | -3.1535 | -2.4 |
| Estimated EPS | -0.4 | -0.36 | None | -1.23 | -4.14 | -4.59 | -1.3 | -1.3 | -1.43 | None | None | -3.24 |
| Surprise | -0.04 | -0.09 | 0 | 0.38 | 2.6 | 0.97 | 0.45 | 0.45 | 0.29 | 0 | 0 | 0.84 |
| Surprise Percentage | -10% | -25% | None% | 30.8943% | 62.8019% | 21.1329% | 34.6154% | 34.6154% | 20.2797% | None% | None% | 25.9259% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHIO
2026-02-24 01:51:57
B2i Digital, Inc. has selected Phio Pharmaceuticals Corp. as a Featured Company due to its promising Phase 1b trial results for lead candidate PH-762 in cutaneous squamous cell carcinoma, showing approximately 65% pathological response with no serious adverse events. Phio Pharmaceuticals has extended its cash runway into the first half of 2027 and plans FDA engagement in Q2 2026 for next-stage clinical development. The company has also strengthened its leadership team and received a reiterated Buy rating with a $14 price target from H.C. Wainwright & Co.
2026-02-23 15:12:25
Phio Pharmaceuticals Corp. has been selected as a B2i Digital Featured Company due to its advancements in its proprietary INTASYL® siRNA gene-silencing technology for cancer treatment. The company reported promising Phase 1b clinical trial results for its lead candidate, PH-762, showing significant pathological response in cSCC with a favorable safety profile. Phio Pharmaceuticals also strengthened its leadership, extended its cash runway into the first half of 2027, and plans FDA engagement in Q2 2026.
2026-02-19 11:57:11
Phio Pharmaceuticals has announced key leadership appointments to support the next stage of development for its PH-762 therapeutic and continued work on PH-894. Lisa Carson has been promoted to Chief Financial Officer, Jennifer Phillips, Pharm.D. to Senior Vice President, Regulatory and Corporate Affairs, and Kimberly Man has joined as Vice President of Program Development and Strategic Planning. These changes aim to strengthen the company's operational readiness for upcoming regulatory discussions and clinical milestones.
2026-02-19 11:57:11
Phio Pharmaceuticals announced key leadership appointments to support the next stage of development for its PH-762 cancer drug and advance PH-894. Lisa Carson was promoted to Chief Financial Officer, Jennifer Phillips to Senior Vice President, Regulatory and Corporate Affairs, and Kimberly Man joined as Vice President of Program Development. These changes aim to strengthen finance, regulatory strategy, and program coordination as the company approaches critical clinical and regulatory milestones.
2026-02-19 07:00:00
Phio Pharmaceuticals has realigned its leadership team, promoting Lisa Carson to Chief Financial Officer and Jennifer Phillips to Senior Vice President, Regulatory and Corporate Affairs. Kimberly Man also joined as Vice President of Program Development and Strategic Planning. These changes aim to strengthen the company's financial and regulatory leadership as it prepares for key regulatory discussions and clinical milestones for PH-762 and continues work on PH-894.
2026-02-18 21:57:33
Phio Pharmaceuticals (PHIO) has amended its CEO Robert J. Bitterman's employment agreement, increasing his severance to 12 months' base salary and raising his target bonus opportunity to 50% of his base salary. This move aims to strengthen executive retention and align incentives amidst the company's strategic priorities. Despite weak financial performance and a bearish technical trend, the company has positive corporate developments for PH-762 and a low-debt balance sheet.
